Skip to main content


Our Thought Leaders Frequently Contribute to Industry Publications & Research Papers

Got a Question? Contact Us
Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes
Statistical Monitoring of Data Quality and Consistency in the Stomach Cancer Adjuvant Multi-Institutional Trial Group Trial
Data-Driven Risk Identification in Phase III Clinical Trials Using Central Statistical Monitoring
The Role of Biostatistics in the Prevention, Detection, and Treatment of Fraud in Clinical Trials
A Statistical Approach to Central Monitoring of Data Quality in Clinical Trials
Centralized Statistical Monitoring as a Way to Improve the Quality of Clinical Data
Linear Mixed-Effects Models for Central Statistical Monitoring of Multicenter Clinical Trials
Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials
A Hercule Poirot of Clinical Research
Ensuring Trial Validity by Data Quality Assurance and Diversification of Monitoring Methods
Fraud in Clinical Trials: Complex Problems, Simple Solutions?
Impact of On-Site Initiation Visits on Patient Recruitment and Data Quality in a Randomized Trial of Adjuvant Chemotherapy for Breast Cancer
Data Fraud in Clinical Trials
Quality Tolerance Limits’ Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters
Paving the path for risk-based quality management and sharing insight at DIA Global
Interview: How CluePoints is making clinical trials 'safer, streamlined and more efficient'
Industry Trends: Cycle Time to Resolve Risk Signals
Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring
The Role of KRIs in Process-Driven RBQM Success
Quality Tolerance Limits: A Review of Industry Trends
The Role of Transferable Skills and Data Science in the Move to Digitally-Enabled Clinical Research
Identifying Important Risk Indicators in Clinical Development
RBQM: A Natural Evolution to Achieve Gold Standard Clinical Trial Management (Pages 38-39)
Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes
Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes
The Eradication of False Signals in Monitoring
Detection of Atypical Data in Multicenter Clinical Trials Using Unsupervised Statistical Monitoring
Achieving Successful Decentralized Trials by Leveraging RBQM and Centralized Monitoring Oversight
Clinical Research: Causing a Wave of New Career Opportunities
Unlocking the Potential of Risk-Based Quality Monitoring
Risk-Based Quality Management Perfect for DCTS
Why Risk-Based Quality Management Represents the Future of Clinical Research
Managing Clinical Trials Amid the Coronavirus Pandemic
Effective Risk Management When Using eCOA and ePRO
Leveraging Audit Trails to Monitor Clinical Study Risk
Using Statistics to Improve Data Quality and Maximize Trial Success
How ICH E6 (R2) Provides a Win/Win/Win through Risk-Based Study Execution
From RBM to RBx: The Keys to Successful Adoption and Implementation
What Does Risk Mean?
Leveraging Intelligent Analytics to Realize the Full Value of RBx and Compliance with ICH E6 (R2)
FDA Offers Further RBM Guidance Stressing Data Quality Oversight
How SMEs Can Achieve Regulatory Compliance Through a Risk-Based Approach
Update on ICH E6 (R2) Guideline for GCP
A Revolutionary Cure for RBM and Centralized Monitoring
The Bigger Picture of the ICH E6 (R2) – Looking Beyond Compliance
ICH E6 (R2) – Miracle Pill for the Clinical R&D Industry

Got a Question?

Whether you’re looking to get started or need support, we’re here to help!

Featured Whitepaper

ICH E6 (R2)

Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.

Learn More

Featured Webinar

ICH E6 (R2)

This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.

Learn More

We're Kind of a Big Deal.


Platform Users


Studies De-Risked


Issues Detected